BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2026)
BioNTech SE (BNTX) reported Income from Continuing Operations of $298.54 million for Q3 2026, up 227.0% from $91.3 million a year earlier.
Powered by 
Analysis
BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, BioNTech SE's Income from Continuing Operations came in at -$1.63 billion; for FY2025, it was -$1.28 billion.
- By year, Income from Continuing Operations came in at -$720.08 million in FY2024, $1.01 billion in FY2023 (-89.9%), $9.94 billion in FY2022 (-18.4%) and $12.18 billion in FY2021.
- The Q3 2026 figure ranks as the highest quarterly Income from Continuing Operations since Q4 2024.
- The high point for year-over-year Income from Continuing Operations in five years was Q3 2026 (growth of 227.0%); the low point was Q3 2023 (a decline of 89.8%).
- Per Business Quant data, the three quarters before Q3 2026 came in at -$1.04 billion (Q2 2026), -$707.48 million (Q1 2026) and -$174.37 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.25 Bn |
| 10 | BioNTech SE | 21.19 Bn | -49.68 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 298.54 Mn |
| Jun 30, 2026 | -1.04 Bn |
| Mar 31, 2026 | -707.48 Mn |
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 366.42 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 7.16 Bn |
API Access
BioNTech SE Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=BNTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "BNTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=BNTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();